- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07333443
Caffeine and Sport Climbing Performance (Climbing&CAF)
Caffeine Ingestion at Acute and Moderate Doses Does Not Improve Sport Climbing Performance: Results From a Randomized Controlled Trial.
Study Overview
Status
Intervention / Treatment
Detailed Description
Introduction: Caffeine is widely recognized as a performance-enhancing substance across numerous athletic disciplines; however, its role in sport climbing has received comparatively limited scientific attention. Because climbing performance relies heavily on grip force, explosive upper-body strength, and localized muscular endurance, this investigation evaluated the short-term impact of a low caffeine dose on climbing-relevant performance outcomes.
Objective: To determine the effects of ingesting caffeine at a dose of 3 mg/kg body mass on pull-up performance and handgrip-related measures in trained climbers.
Methods: Thirteen trained young male climbers participated in a triple-blind, randomized, crossover study design, completing two experimental conditions (caffeine and placebo). Performance assessments included a pull-up one-repetition maximum (1RM), a pull-up power test conducted at multiple external loads, a pull-up endurance test, and several grip performance evaluations, namely maximal dead-hang duration, maximal dead-hang force, and rate of force development (RFD).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Madrid
-
Alcalá de Henares, Madrid, Spain, 28805
- Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion criteria:
- Healthy individuals
- Age between 18 and 40 years
- At least three months of continuous climbing practice
- Ability to hang for at least 5 seconds from an 18-mm edge
- Ability to perform at least one strict body-weight pull-up
Exclusion criteria:
- Any musculoskeletal or medical condition preventing completion of the experimental protocol
- Participation in less than three training sessions per week or a total training volume <150 min/week
- Use of medications or dietary supplements known to affect caffeine metabolism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
0 mg/kg of caffeine
|
Placebo supplementation was provide to young male climbers.
|
|
Experimental: Caffeine
3 mg/kg of caffeine
|
Caffeine supplementation was provide to young male climbers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pull-up 1RM
Time Frame: Through study completion, an average of 4 weeks
|
Through study completion, an average of 4 weeks
|
|
|
Pull-up strength and power test 1
Time Frame: Through study completion, an average of 4 weeks
|
Mean and peak velocity will be recorded at 60%, 80%, 90%, 95% and 100% 1RM.
|
Through study completion, an average of 4 weeks
|
|
Pull-up strength and power test 2
Time Frame: Through study completion, an average of 4 weeks
|
Mean and peak power will be recorded at 60%, 80%, 90%, 95% and 100%1RM.
|
Through study completion, an average of 4 weeks
|
|
Pull-up muscular endurance test
Time Frame: Through study completion, an average of 4 weeks
|
Using body mass and perform one set of many repetitions as possible until task failure.
The total number of repetitions, Vmean, Vpeak, Wmean and Wpeak were recorded.
|
Through study completion, an average of 4 weeks
|
|
Grip endurance in dead-hang.
Time Frame: Through study completion, an average of 4 weeks
|
Maximum hanging time (MHT) test at an 18-mm edge depth with each hand
|
Through study completion, an average of 4 weeks
|
|
Maximum grip strength in dead-hang
Time Frame: Through study completion, an average of 4 weeks
|
using the Strength Test (ST), which measures the maximal external load a participant can sustain for 5 seconds while hanging from an 18-mm edge
|
Through study completion, an average of 4 weeks
|
|
Grip rate of force development (RFD).
Time Frame: Through study completion, an average of 4 weeks
|
measuring the maximal one-hand pull (voluntary contraction) at an 18 mm edge with a force sensor
|
Through study completion, an average of 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body composition
Time Frame: Through study completion, an average of 4 weeks
|
Using bioelectrical impedance
|
Through study completion, an average of 4 weeks
|
|
Dietary habits
Time Frame: Through study completion, an average of 4 weeks
|
24 h dietary recall
|
Through study completion, an average of 4 weeks
|
|
Mood states
Time Frame: Through study completion, an average of 4 weeks
|
Using the Profile of Mood States (POMS) on a 0-4 scale.
|
Through study completion, an average of 4 weeks
|
|
Physical activity habits
Time Frame: Through study completion, an average of 4 weeks
|
International Physical Activity Questionnaire (IPAQ).
Report the unabbreviated scale title.
Scores are typically expressed as MET-minutes/week or by activity categories (low, moderate, high), depending on the scoring protocol used.
There is no fixed universal minimum or maximum score for MET-minutes/week, as scores depend on reported activity levels.
Higher scores indicate better outcomes (greater physical activity).
|
Through study completion, an average of 4 weeks
|
|
Rate of perceived exertion
Time Frame: Through study completion, an average of 4 weeks
|
Using Rating of Perceived Exertion (RPE).
Category Ratio 10 (CR10) Scale: minimum 0, maximum 10 (or 11 if including "maximal").
Higher scores indicate worse outcomes (greater perceived exertion).
|
Through study completion, an average of 4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alberto Pérez López, PhD, University of Alcala
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CEIP/2024/5/117 (Other Identifier: CEIP/2024/5/117)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Caffeine
-
Ain Shams UniversityCompletedCaffeine | Caffeine Withdrawal | Caffeine DependenceEgypt
-
Psychiatric Hospital of the University of BaselSwiss National Science FoundationCompletedSleep | Circadian Rhythm | Caffeine | Caffeine WithdrawalSwitzerland
-
St. Mary's University, TwickenhamNot yet recruiting
-
St Mary's University CollegeNot yet recruiting
-
Ege UniversityThe Scientific and Technological Research Council of TurkeyCompletedCaffeineTurkey (Türkiye)
-
Wake Forest University Health SciencesThe Hershey CompanyCompleted
-
Technical University of LisbonCompleted
-
St. Mary's University, TwickenhamNot yet recruiting
-
Yu-Shiuan LinActive, not recruiting
-
Chih-Hui ChiuCompleted
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States